Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued Treatment.

作者信息

Flaherty Keith T, Brose Marcia S

机构信息

Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania.

出版信息

Clin Cancer Res. 2009 Dec 15;15(24):7749. doi: 10.1158/1078-0432.CCR-09-1190.

DOI:10.1158/1078-0432.CCR-09-1190

PMID:20008857

Abstract

摘要

相似文献

Clin Cancer Res. 2009 Dec 15;15(24):7749. doi: 10.1158/1078-0432.CCR-09-1190.

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.

Br J Dermatol. 2008 Mar;158(3):592-6. doi: 10.1111/j.1365-2133.2007.08357.x. Epub 2007 Dec 6.

Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma.

Pediatr Dermatol. 2009 May-Jun;26(3):349-50. doi: 10.1111/j.1525-1470.2009.00933.x.

Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.

Arch Dermatol. 2008 Jul;144(7):886-92. doi: 10.1001/archderm.144.7.886.

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

J Clin Oncol. 2006 Jun 1;24(16):2505-12. doi: 10.1200/JCO.2005.03.6723. Epub 2006 Apr 24.

Sorafenib for the treatment of advanced renal cell carcinoma.

Clin Cancer Res. 2006 Dec 15;12(24):7271-8. doi: 10.1158/1078-0432.CCR-06-1249.

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

Oncologist. 2007 Apr;12(4):426-37. doi: 10.1634/theoncologist.12-4-426.

Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.

J Clin Oncol. 2009 Sep 10;27(26):4274-80. doi: 10.1200/JCO.2009.22.0541. Epub 2009 Aug 3.

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.

Cancer. 2010 Mar 1;116(5):1272-80. doi: 10.1002/cncr.24864.

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.

Anticancer Drugs. 2009 Aug;20(7):616-24.

引用本文的文献

Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel.

An Bras Dermatol. 2020 Mar-Apr;95(2):221-237. doi: 10.1016/j.abd.2020.01.001. Epub 2020 Feb 15.

Selective use of sorafenib in the treatment of thyroid cancer.

Drug Des Devel Ther. 2016 Mar 11;10:1119-31. doi: 10.2147/DDDT.S82972. eCollection 2016.

Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer.

Onco Targets Ther. 2015 Sep 3;8:2435-42. doi: 10.2147/OTT.S86322. eCollection 2015.

Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma.

Cancer Res. 2015 Jun 15;75(12):2510-9. doi: 10.1158/0008-5472.CAN-14-3687. Epub 2015 Apr 23.

Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.

Open Access J Urol. 2011 May 10;3:69-82. doi: 10.2147/OAJU.S7230.

Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.

Invest New Drugs. 2012 Oct;30(5):2001-7. doi: 10.1007/s10637-011-9761-y. Epub 2011 Oct 21.

Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience.

Ther Adv Med Oncol. 2011 Mar;3(2):95-100. doi: 10.1177/1758834010396117.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验